| Primary |
| Hiv Infection |
67.1% |
| Drug Exposure During Pregnancy |
13.5% |
| Acquired Immunodeficiency Syndrome |
6.5% |
| Hiv Test Positive |
3.4% |
| Gestational Diabetes |
2.7% |
| Hypertension |
1.3% |
| Epilepsy |
0.8% |
| Chronic Obstructive Pulmonary Disease |
0.6% |
| Hiv Infection Cdc Category A3 |
0.6% |
| Hyperkeratosis |
0.5% |
| Antiretroviral Therapy |
0.3% |
| Convulsion |
0.3% |
| Diabetes Mellitus |
0.3% |
| Diarrhoea |
0.3% |
| Herpes Virus Infection |
0.3% |
| Hiv Infection Cdc Category C3 |
0.3% |
| Pulmonary Embolism |
0.3% |
| Type 1 Diabetes Mellitus |
0.3% |
| Antibiotic Prophylaxis |
0.2% |
| Coagulopathy |
0.2% |
|
| Malnutrition |
13.3% |
| Umbilical Cord Abnormality |
10.9% |
| Haemorrhage Intracranial |
7.8% |
| Overdose |
7.8% |
| Aspartate Aminotransferase Increased |
6.3% |
| Liver Function Test Abnormal |
6.3% |
| Drug Ineffective |
4.7% |
| Hepatotoxicity |
4.7% |
| Death |
3.9% |
| Drug Interaction |
3.9% |
| Gastrointestinal Disorder |
3.9% |
| Transaminases Increased |
3.9% |
| Treatment Noncompliance |
3.9% |
| Premature Labour |
3.1% |
| Rash |
3.1% |
| Varices Oesophageal |
3.1% |
| Blood Bilirubin Increased |
2.3% |
| Cerebral Haemorrhage |
2.3% |
| Headache |
2.3% |
| Hepatic Function Abnormal |
2.3% |
|
| Secondary |
| Hiv Infection |
43.2% |
| Drug Use For Unknown Indication |
36.3% |
| Acquired Immunodeficiency Syndrome |
3.7% |
| Drug Exposure During Pregnancy |
2.9% |
| Antiretroviral Therapy |
2.6% |
| Retroviral Infection |
1.9% |
| Product Used For Unknown Indication |
1.5% |
| Gestational Diabetes |
1.1% |
| Hiv Test Positive |
1.1% |
| Pulmonary Embolism |
0.9% |
| Convulsion |
0.8% |
| Antifungal Prophylaxis |
0.7% |
| Hypertension |
0.7% |
| Maternal Exposure Timing Unspecified |
0.7% |
| Hiv Infection Cdc Category C3 |
0.5% |
| Antiviral Prophylaxis |
0.5% |
| Viral Infection |
0.4% |
| Epilepsy |
0.3% |
| Drug Resistance |
0.2% |
| Multiple-drug Resistance |
0.2% |
|
| Haemorrhage Intracranial |
11.5% |
| Meningitis Cryptococcal |
11.5% |
| Umbilical Cord Abnormality |
10.5% |
| Cerebral Haemorrhage |
8.9% |
| Varices Oesophageal |
8.9% |
| Death |
4.7% |
| Liver Function Test Abnormal |
4.7% |
| Mental Status Changes |
4.2% |
| Vomiting |
4.2% |
| Aspartate Aminotransferase Increased |
3.7% |
| Overdose |
3.7% |
| Premature Labour |
3.7% |
| Hypertension |
3.1% |
| Skin Burning Sensation |
3.1% |
| Drug Interaction |
2.6% |
| Viral Load Increased |
2.6% |
| Weight Decreased |
2.6% |
| Hiv Infection |
2.1% |
| Jaundice |
2.1% |
| Convulsion |
1.6% |
|
| Concomitant |
| Hiv Infection |
79.5% |
| Antiretroviral Therapy |
8.2% |
| Prophylaxis Against Hiv Infection |
3.3% |
| Drug Use For Unknown Indication |
1.6% |
| Pain |
1.6% |
| Sleep Disorder |
1.6% |
| Cerebral Haemorrhage |
0.8% |
| Dyslipidaemia |
0.8% |
| Pneumonia |
0.8% |
| Product Used For Unknown Indication |
0.8% |
| Pulmonary Arterial Hypertension |
0.8% |
|
| Death |
14.6% |
| Diarrhoea |
6.3% |
| Osteomyelitis |
6.3% |
| Renal Failure Chronic |
6.3% |
| Weight Decreased |
6.3% |
| Anaemia |
4.2% |
| Headache |
4.2% |
| Herpes Zoster |
4.2% |
| Lung Neoplasm Malignant |
4.2% |
| Muscle Disorder |
4.2% |
| Osteonecrosis |
4.2% |
| Pharyngitis |
4.2% |
| Renal Failure |
4.2% |
| Renal Impairment |
4.2% |
| Respiratory Failure |
4.2% |
| Sepsis |
4.2% |
| Stevens-johnson Syndrome |
4.2% |
| Subcutaneous Abscess |
4.2% |
| Syncope |
4.2% |
| Appendicitis Perforated |
2.1% |
|
| Interacting |
| Hiv Infection |
43.8% |
| Drug Use For Unknown Indication |
37.5% |
| Antiretroviral Therapy |
18.8% |
|
| Urine Amphetamine Positive |
50.0% |
| Vomiting |
50.0% |
|
